AnaptysBio. has been granted a patent for an IL-33-binding agent composed of isolated immunoglobulin heavy and light chain polypeptides. This agent is designed to treat autoimmune diseases by inhibiting interleukin-33 (IL-33), utilizing specific complementarity-determining regions (CDRs) from the polypeptides. GlobalData’s report on AnaptysBio gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on AnaptysBio, Personalized cancer vaccines was a key innovation area identified from patents. AnaptysBio's grant share as of June 2024 was 23%. Grant share is based on the ratio of number of grants to total number of patents.
Il-33-binding agent for treating autoimmune diseases
The granted patent US11999783B2 outlines a method for treating various autoimmune diseases through the use of an interleukin-33 (IL-33) binding protein. This binding protein is characterized by specific immunoglobulin heavy and light chains, which include complementarity-determining regions (CDRs) identified by SEQ ID NO: 136 and SEQ ID NO: 171, respectively. The patent specifies that the method can be applied to treat a range of autoimmune conditions, including Crohn's disease, rheumatoid arthritis, psoriasis, ankylosing spondylitis, lupus erythematosus, and scleroderma. The IL-33 binding protein can take various forms, such as an antibody, an antibody conjugate, or an antigen-binding fragment, and may include formats like F(ab')2, Fab', Fab, Fv, scFv, dsFv, dAb, or single-chain binding polypeptides.
Additionally, the patent details specific characteristics of the IL-33 binding protein, including a half-life ranging from 30 minutes to 45 days and a binding affinity to IL-33 with a dissociation constant (KD) of less than or equal to 1 nanomolar. The preferred embodiment of the IL-33 binding protein is identified as an IgG1 antibody. This patent presents a targeted approach to modulating immune responses in autoimmune diseases by leveraging the properties of IL-33 and its binding proteins, potentially offering new therapeutic avenues for patients suffering from these conditions.
To know more about GlobalData’s detailed insights on AnaptysBio, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
